Statements (52)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
6
|
| gptkbp:bfsParent |
gptkb:The_Upjohn_Company
|
| gptkbp:activities |
noradrenergic and specific serotonergic antidepressant (Na SSA)
|
| gptkbp:approves |
gptkb:1996
gptkb:FDA |
| gptkbp:brand |
Remeron
Zispin |
| gptkbp:class |
tetracyclic antidepressant
|
| gptkbp:clinical_trial |
Phase III
|
| gptkbp:contraindication |
concurrent use of MAO Is
hypersensitivity to mirtazapine |
| gptkbp:dosage_form |
gptkb:tablet
orally disintegrating tablet 15 to 45 mg daily |
| https://www.w3.org/2000/01/rdf-schema#label |
Mirtazapine
|
| gptkbp:ingredients |
C17 H19 N3
|
| gptkbp:interacts_with |
gptkb:beer
benzodiazepines monoamine oxidase inhibitors (MAO Is) |
| gptkbp:is_atype_of |
N06 A X11
|
| gptkbp:is_available_in |
tablets
orally disintegrating tablets |
| gptkbp:is_available_on |
generic drug
|
| gptkbp:is_used_for |
major depressive disorder
|
| gptkbp:lifespan |
20 to 40 hours
|
| gptkbp:manager |
oral
|
| gptkbp:metabolism |
liver
|
| gptkbp:mood |
elevates mood
|
| gptkbp:requires |
prescription only
|
| gptkbp:research_areas |
depression treatment
anxiety treatment insomnia treatment |
| gptkbp:side_effect |
fatigue
headache nausea vomiting drowsiness constipation dry mouth weight gain sedation increased appetite increases appetite reduces anxiety symptoms |
| gptkbp:sleeping_habits |
improves sleep quality
|
| gptkbp:symptoms |
anxiety
nausea irritability insomnia |
| gptkbp:type_of |
85650-52-8
|
| gptkbp:uses |
tolerance to sedative effects
|